| Abstrakt: |
Keywords: Business; Cancer; Clinical Research; Clinical Trials and Studies; Connective Tissue Cells; Drugs and Therapies; Fibroblasts; Health and Medicine; Indicators and Reagents; Oncology; Pharmacokinetics; Pharmacology; Radiopharmaceuticals; Ratio Therapeutics Inc EN Business Cancer Clinical Research Clinical Trials and Studies Connective Tissue Cells Drugs and Therapies Fibroblasts Health and Medicine Indicators and Reagents Oncology Pharmacokinetics Pharmacology Radiopharmaceuticals Ratio Therapeutics Inc 535 535 1 07/24/23 20230725 NES 230725 2023 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers announced, in partnership with Lantheus, a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and in collaboration with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, that it has initiated dosing in a Phase I study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, Copper-64[Cu-64]-labeled RTX-1363S, for PET imaging in adult healthy volunteers. "Cancer-associated fibroblasts selectively expressing FAP comprise up to 90% of the tumor mass in highly desmoplastic cancers, including pancreatic, breast, and colorectal. [Extracted from the article] |
